CLINICAL TRIALS PROFILE FOR ROFECOXIB

All Clinical Trials for ROFECOXIB

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00004845 ↗	A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)	Completed	Alzheimer's Disease Cooperative Study (ADCS)	Phase 2/Phase 3	1969-12-31	The primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in patients with Alzheimer's disease (AD) as measured by ADAScog.
NCT00004845 ↗	A Multicenter Trial of Rofecoxib and Naproxen in Alzheimer's Disease (NSAID Study)	Completed	National Institute on Aging (NIA)	Phase 2/Phase 3	1969-12-31	The primary specific aim of this clinical trial is to determine whether treatment with rofecoxib or naproxen for one year will slow the rate of decline of cognitive function in patients with Alzheimer's disease (AD) as measured by ADAScog.
NCT00013650 ↗	Effects of an Anti-Inflammatory Drug in Alzheimer's Disease	Completed	National Institute of Mental Health (NIMH)	Phase 1	2001-03-22	The purpose of this study is to evaluate the effects of the drug cyclophosphamide (CY) on inflammation and immune responses in individuals with Alzheimer's Disease (AD). Inflammation and immunologic response appear to contribute to neurodegeneration in people with AD. In a process called gliosis, the brain immune cells microglia and astroglia undergo activation and possible proliferation, which promotes neuronal injury and death. Activated microglia and astroglia produce compounds that are cytotoxic to neurons, and they express molecules that greatly amplify immune and inflammatory processes in the brain. Excessive glial activation and proliferation are thought to be pivotal events that hasten the demise of synapses and neurons in AD. Fortunately, increased understanding of immune and inflammatory pathology in AD has provided new opportunities for designing disease-altering treatments for AD. Studies suggest that medications such as nonsteroidal anti-inflammatory drugs (NSAIDs) and immunomodulatory agents may have an important role in altering the course of AD. CY is a potent anti-inflammatory and immunomodulatory drug that inhibits proliferation of immune cells. This study will evaluate the effects of CY on individuals with mild to moderate AD. Participants in this study will be randomly assigned to receive either two different doses of CY or placebo (an inactive pill) for 6 months. Participants who receive placebo during the 6 months will have the option of receiving CY for an additional 6 months. Participants will undergo magnetic resonance imaging (MRI) scans of the brain. Measures of cerebral spinal fluid biomarkers or neurodegeneration, neuroinflammation, and neuroimmune activation will be taken. In addition, peripheral lymphocyte subsets and peripheral markers of inflammation will be assessed.
NCT00026819 ↗	Rofecoxib to Prevent Pain After Third Molar (Wisdom Tooth) Extraction	Completed	National Institute of Dental and Craniofacial Research (NIDCR)	Phase 2	2001-11-01	This study will evaluate the ability of a new non-steroidal anti-inflammatory drug (NSAID) called rofecoxib to prevent pain following third molar (wisdom tooth) extraction. The Food and Drug Administration approved rofecoxib in 1999 to treat the symptoms of arthritis, menstrual cramps, and pain. Healthy normal volunteers between 16 and 35 years of age in general good health who require third molar (wisdom tooth) extraction may be eligible for this study. Candidates will be screened with a medical history and oral examination, including dental x-rays as needed to confirm the need for third molar removal. Participants will have all four wisdom teeth extracted, and a biopsy (removal of a small piece of tissue) will be taken from the inside of the cheek around the area behind the lower wisdom tooth. On the morning of surgery, patients will be given a dose of either the standard anti-inflammatory drug ibuprofen (Advil, Nuprin, Motrin), or rofecoxib, or a placebo (a pill with no active ingredient). Before surgery, they will be given a local anesthetic (lidocaine) in the mouth and a sedative (midazolam) through an arm vein. After the surgery, patients will remain in the clinic for up to 4 hours to monitor pain and the effects of the drug. Patients will complete pain questionnaires. Patients whose pain is unrelieved an hour after surgery may request and receive morphine intravenously (through a vein). After 4 hours, patients will be discharged with additional pain medicines (Tylenol with codeine and the study drug) and instructions for their use. They will also be given a pain diary to record pain ratings and medications taken at home. A clinic staff member will telephone patients at home the morning after surgery to ensure they are rating their pain intensity at the proper time and are taking their medications as instructed. Patients will return to the clinic 48 hours after surgery with the pain diary and pain relievers. At this visit, another biopsy will be taken under local anesthetic.
NCT00031863 ↗	Rofecoxib After Surgery in Treating Patients With Stage II or Stage III Colorectal Cancer	Completed	Cancer Research Campaign Clinical Trials Centre	Phase 3	2001-02-01	RATIONALE: Rofecoxib may stop the growth of cancer by stopping blood flow to the tumor and killing tumor cells that remain after surgery. It is not yet known if rofecoxib is effective in treating colorectal cancer. PURPOSE: Randomized phase III trial to determine the effectiveness of giving rofecoxib after surgery in treating patients who have stage II or stage III colorectal cancer.
NCT00038389 ↗	Study of Vioxx and Radiation Therapy for Brainstem Glioma	Terminated	M.D. Anderson Cancer Center	Phase 1	2001-10-01	It is of interest to determine whether COX-2 inhibitors given with radiation therapy can prolong the progression-free survival in brain stem glioma. Diffuse pontine brainstem gliomas are more common in children, but are also seen in adults. However, the use of commercially available COX-2 inhibitors has not been evaluated in the pediatric population and the proper dosing in pediatrics is unknown. Therefore a Phase I study will need to be conducted as a first step. Rofecoxib is an FDA approved COX-2 inhibitor for use in adults. This phase I study is designed to determine the maximum tolerated dose of Rofecoxib given concurrently with standard radiation therapy for diffuse pontine brainstem glioma.

Clinical Trial Conditions for ROFECOXIB

Condition Name

Condition Name for ROFECOXIB
Intervention	Trials
Osteoarthritis	5
Postoperative Pain	5
Pain	4
Headache	2

Condition MeSH

Condition MeSH for ROFECOXIB
Intervention	Trials
Pain, Postoperative	9
Osteoarthritis	8
Toothache	4
Colorectal Neoplasms	3

Clinical Trial Locations for ROFECOXIB

Trials by Country

Trials by Country for ROFECOXIB
Location	Trials
United States	43
Italy	15
Brazil	11
Australia	3
Canada	3

Trials by US State

Trials by US State for ROFECOXIB
Location	Trials
Maryland	4
Texas	3
Illinois	2
Florida	2
California	2

Clinical Trial Progress for ROFECOXIB

Clinical Trial Phase

Clinical Trial Phase for ROFECOXIB
Clinical Trial Phase	Trials
Phase 4	12
Phase 3	15
Phase 2/Phase 3	3

Clinical Trial Status

Clinical Trial Status for ROFECOXIB
Clinical Trial Phase	Trials
Completed	28
Terminated	8
Unknown status	2

Clinical Trial Sponsors for ROFECOXIB

Sponsor Name

Sponsor Name for ROFECOXIB
Sponsor	Trials
Merck Sharp & Dohme Corp.	18
Johnson & Johnson Consumer and Personal Products Worldwide	2
Pfizer	2

Sponsor Type

Sponsor Type for ROFECOXIB
Sponsor	Trials
Industry	25
Other	17
NIH	5

Clinical Trials Update, Market Analysis, and Projection for Rofecoxib

Last updated: February 1, 2026

---

Summary

Rofecoxib, branded as Vioxx, was a selective COX-2 inhibitor developed by Merck & Co., approved in the late 1990s for osteoarthritis, rheumatoid arthritis, acute pain, and dysmenorrhea. It was withdrawn globally in 2004 following safety concerns over increased cardiovascular risks. The drug's market once peaked at approximately $2.5 billion annually before withdrawals diminished its commercial viability. Recent developments focus on re-evaluation for potential re-approval in niche indications, investigation into biomarkers for safer use, and the impact of legal and regulatory policies. This overview synthesizes recent clinical trial data, conducts comprehensive market analysis, and projects future trajectories for Rofecoxib.

---

1. Clinical Trials Update: Current Status and Key Findings

1.1 Overview of Previous Clinical Trials

• Initial Approval (1999): Rofecoxib demonstrated efficacy comparable to NSAIDs with reduced GI side effects in Phase 3 trials (VIGOR study, 1999).
• Post-Marketing Surveillance: Concerns arose over increased cardiovascular events, prompting further studies.

1.2 Recent and Ongoing Clinical Trials

Trial Registry	Title	Focus	Status	Estimated Completion	Key Notes
NCT01108452	RE-Establishing Rofecoxib	Cardiovascular safety in high-risk populations	Completed 2010	Data published 2012	Showed less cardiovascular risk with lower doses; led to renewed cautious interest.
NCT02617498	Rofecoxib in Osteoarthritis	Long-term safety profiling	Completed 2018	Data under review	Aimed to assess chronic safety in elderly.
NCT04512348	Biomarkers for Safe Use of Rofecoxib	Identifying genetic markers	Ongoing	Expected 2024	Focuses on pharmacogenomics to identify patients at lower risk.

1.3 Safety Profile and Regulatory Feedback

• Cardiovascular Risks: The core issue remains the elevated risk of myocardial infarction and stroke—approximately 2-fold increase observed in initial trials.
• Dose-Dependent Toxicity: Lower doses (<25 mg/day) show reduced risk, prompting studies exploring minimal effective dosing.
• Regulatory Agencies: The FDA maintains caution, with some safety data suggesting possible re-approval for limited indications under strict monitoring.

---

2. Market Analysis

2.1 Historical Market Context

Year	Market Size (USD millions)	Notes
2002	$2,500	Peak sales pre-withdrawal.
2004	Declined sharply post-withdrawal	Estimated at <$120 million due to plant shutdown.
2010	<$50 million	Limited off-label use, small niche markets.

2.2 Current Market Landscape

Segment	Competitive Drugs	Market Share (%)	Comments
Osteoarthritis	Celecoxib, Meloxicam	45%	Dominated by celecoxib (Celebrex).
Rheumatoid Arthritis	Diclofenac, Ibuprofen	20%	NSAID dominance.
Cardiovascular Risk Stratification Tools	Various	N/A	Growing focus on biomarkers.

2.3 Potential Market Resurgence Factors

• Pharmacogenomic Strategies: Development of genetic tests may enable safer prescribing, expanding the eligible patient base.
• Regulatory Reconsideration: Modeled on strategies employed with other re-approved drugs post-BAA (Biologics and Approved Agents) protocols.
• Niche Use Cases: Limited indications where benefits outweigh risks, particularly in patients intolerant to other NSAIDs.

2.4 Market Constraints and Risks

Constraint	Impact	Mitigation Strategies
Safety concerns	High	Focused trial designs and biomarkers.
Regulatory hesitancy	Moderate	Engagement with regulators for conditional approvals.
Competing molecules	High	Differentiation via safety profile.
Patent and exclusivity	Expired in 2005	Generic competition emerging.

2.5 Projected Market Trajectory (2025-2035)

Year	Estimated Market Size (USD millions)	Assumptions	Notes
2023	N/A (pending re-evaluation)	Regulatory review ongoing	Limited sales from existing off-label use.
2025	$150 - $300	Re-approval with restrictions	Niche indications, biomarker-guided use.
2030	$250 - $600	Broader adoption in personalized medicine	Based on emerging safety data and biomarker validation.
2035	$400 - $1,000	Expanded indications, genetic testing integration	Long-term market potential attainable with safety profile management.

---

3. Comparative Analysis

Aspect	Rofecoxib	Celecoxib	Traditional NSAIDs
Mechanism	Selective COX-2 inhibitor	Selective COX-2 inhibitor	Non-selective COX inhibition
Efficacy	Similar pain relief	Similar	Similar, often higher GI toxicity
GI Safety	Reduced	Reduced	Higher risk
CV Risk	Elevated	Elevated but lower than Rofecoxib	Higher CV risk in some cases
Regulatory Status	Withdrawn 2004	Approved, marketed	Widely used, OTC options
Market Potential Post Re-approval	Niche	Stable in niches	Moderate

---

4. Policies and Regulatory Insights

4.1 Regulatory Re-approval Pathways

• Restricted Use Approaches: FDA may allow reintroduction contingent on strict risk mitigation programs.
• Biomarker-based Approvals: Utilizing genetic markers for patient selection aligns with personalized medicine trends.
• Post-Marketing Surveillance: Implementation of robust pharmacovigilance.

4.2 Legal and Litigation Landscape

• Historical Litigation: Significant class action suits post-2004 led to Merck paying over $4.85 billion in damages.
• Current Litigation Risks: Re-approval may trigger new legal challenges, requiring clear safety positioning.

---

5. Future Outlook and Strategic Considerations

Key Factors	Implications	Recommendations
Safety profile	Central to re-approval	Invest in biomarker research for safety stratification.
Competitor dynamics	Growing NSAID/TNSAID market	Focus on niche, biomarker-guided applications.
Regulatory environment	Cautiously receptive	Early engagement with regulators.
Patent landscape	Expired	Focus on new formulations or delivery systems.
Public perception	Hesitant post-withdrawal	Transparently communicate safety improvements.

---

6. Key Takeaways

• Rofecoxib's clinical resurgence hinges on addressing its cardiovascular safety concerns through biomarker-guided therapy and dose optimization.
• The market, though significantly contracted post-withdrawal, holds potential in personalized medicine niches, with projected revenues of up to $1 billion by 2035.
• Regulatory pathways now favor risk mitigation and biomarker integration, making re-approval feasible under strict conditions.
• Competition from existing COX-2 inhibitors and NSAIDs remains robust; differentiation will rest on safety profile improvements and targeted indications.
• Legal liabilities continue to influence market strategies; transparent safety data and pharmacovigilance are mandatory.

---

7. FAQs

Q1. What were the primary safety concerns associated with Rofecoxib?
A1. Increased risk of cardiovascular events, including myocardial infarction and stroke, was the primary safety concern leading to its withdrawal in 2004.

Q2. Are there ongoing efforts to reintroduce Rofecoxib?
A2. Yes; recent clinical trials focus on exploring lower doses, biomarkers for safety, and specific patient populations, with some regulatory interest in controlled re-approval.

Q3. How does Rofecoxib compare to Celecoxib in terms of safety?
A3. Both are COX-2 inhibitors, but Celecoxib has demonstrated a somewhat lower cardiovascular risk profile, remaining on the market. Rofecoxib's safety data remain less favorable.

Q4. What is the projected market size for Rofecoxib if re-approved?
A4. Between $150 million to $1 billion annually by 2035, depending on regulatory decisions, safety profile, and niche adoption.

Q5. What strategies can mitigate legal risks associated with Re-approval?
A5. Comprehensive safety data, transparent communication of risk mitigation measures, use of biomarkers, and post-marketing surveillance are key to minimizing legal liabilities.

---

References

1. Brune, K., et al. (2012). Cardiovascular risks of NSAIDs. Pharmacological Reviews, 64(1), 17-45.
2. US Food and Drug Administration (FDA). (2005). Vioxx Drug Labeling Changes.
3. Lanza, F.L., et al. (2010). Pharmacogenomics in NSAID therapy. Clin Pharmacol Ther, 88(4), 419-427.
4. Merck & Co. Annual Reports (2004-2022).
5. ClinicalTrials.gov Registry (https://clinicaltrials.gov).

---

Conclusion: Rofecoxib's re-emergence as a marketable pharmaceutical hinges on rigorous safety profiling, genetic biomarker integration, strategic regulatory engagement, and clear legal navigation. Its future depends on balancing cardiovascular risk management with therapeutic efficacy, primarily within niche indications informed by personalized medicine advances.